Programmed cell death 1 (PD-1) and its ligand (PD-L1) are expressed in 28-40% of patients with ovarian cancer (13, 14), and thus, anti-PD-1 therapy could be considered a rational strategy for the targeted treatment of ovarian cancers. The gene discussed is PDCD1; the disease is ovarian carcinoma.